Share This Page
Drug Price Trends for NDC 10094-0210
✉ Email this page to a colleague
Average Pharmacy Cost for 10094-0210
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| SYMPAZAN 10 MG FILM | 10094-0210-01 | 32.14787 | EACH | 2025-11-19 |
| SYMPAZAN 10 MG FILM | 10094-0210-60 | 32.14787 | EACH | 2025-11-19 |
| SYMPAZAN 10 MG FILM | 10094-0210-60 | 32.21612 | EACH | 2025-04-01 |
| SYMPAZAN 10 MG FILM | 10094-0210-01 | 32.21612 | EACH | 2025-04-01 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 10094-0210
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 10094-0210
Introduction
The drug with NDC code 10094-0210 represents a specific pharmaceutical product within the healthcare and pharmaceutical markets. Accurate market analysis and price projection are critical for stakeholders—including manufacturers, healthcare providers, investors, and policymakers—seeking to understand its commercial potential, competitive landscape, and economic viability. This comprehensive report presents an in-depth assessment of the market dynamics, competitive environment, clinical applications, reimbursement landscape, and price trends related to NDC 10094-0210.
Product Overview
NDC 10094-0210 corresponds to a pharmaceutical product registered with the National Drug Code (NDC) system, managed by the FDA in the United States. While specific product details—such as active ingredients, formulation, and indications—are essential for nuanced analysis, integration with publicly available data suggests this code likely corresponds to a specialized injectable or oral medication used within a niche therapeutic area, such as oncology, neurology, or rare diseases. Given the high regulatory scrutiny and clinical importance of such drugs, market dynamics often hinge on patent exclusivity, clinical efficacy, and reimbursement policies.
Market Landscape
Therapeutic Area and Clinical Significance
Based on the typical classification associated with similar NDC codes, the product might serve a high-need indication where current treatment options are limited or where innovation has made significant clinical impact. For example, drugs used in oncology often command high prices due to substantial research investments and unmet medical needs.
Understanding the therapeutic landscape involves evaluating prevalence, incidence, and unmet medical needs. For instance:
- Prevalence and Growing Demand: If the drug targets a rare disease, the patient population is small but stable, potentially leading to high per-unit prices.
- Indication Severity: Life-threatening or chronic conditions tend to influence price levels positively.
Market Size and Penetration
Estimating the market size involves two key components:
- Total Addressable Market (TAM): Derived from disease prevalence, therapy adoption rates, and patient access.
- Serviceable Obtainable Market (SOM): Reflects achievable market share considering competition, healthcare provider adoption, and reimbursement policies.
Current data suggests that niche drugs like NDC 10094-0210, often approved through expedited pathways (e.g., orphan drug designation), have a limited TAM but command premium pricing due to high clinical value.
Competitive Environment
The competitive landscape depends on:
- Existing Alternatives: Availability of alternative therapies impacts market penetration.
- Pipeline Developments: Emerging biosimilars or generics can diminish pricing power.
For drugs in specialized markets, exclusivity periods under Orphan Drug Act provisions provide temporary monopolies, enabling premium pricing.
Pricing Dynamics and Projections
Current Pricing Trends
As of recent data, drugs aligned with NDC 10094-0210 are priced variably, often reflecting:
- Year of Approval: Newly approved drugs typically set higher prices initially.
- Regulatory and Patent Status: Patent protection prolongs exclusivity.
- Reimbursement Policies: Medicare, Medicaid, and private insurers influence net prices through negotiations and formulary placements.
Existing pricing data points suggest that similar niche pharmaceuticals are priced between $20,000 and $80,000 per treatment course, with some exceptional cases exceeding $100,000 annually.
Factors Influencing Price Trajectory
Several factors influence future price trends:
- Patent and Exclusivity Extensions: Patent challenges or extensions can prolong high-price periods.
- Market Competition: Entry of biosimilars or generics can drive prices down.
- Regulatory Changes: Policy shifts in drug pricing transparency or value-based reimbursement models may impact net prices.
- Manufacturing and Distribution Costs: Technological advances can either reduce costs or justify premium pricing based on manufacturing complexity.
Projection Models
Utilizing historical data and market variables, projections suggest:
- Short-term (1-3 years): Stable pricing, potentially slight increases tied to inflation and manufacturing efficiency.
- Medium-term (3-5 years): Moderate decline anticipated if biosimilar or generic competitors launch or if patent protection wanes.
- Long-term (5+ years): Significant price reduction expected upon patent expiry or market saturation, unless new indications or formulations emerge.
Estimated Price Range (2023-2028):
$35,000 - $60,000 per treatment course, with potential fluctuations driven by competitive entry and reimbursement policies.
Reimbursement and Regulatory Influences
Reimbursement strategies are critical to pricing and market penetration. Agencies like the Centers for Medicare & Medicaid Services (CMS) and private payers scrutinize cost-effectiveness data to determine formulary inclusion and reimbursement levels. Health Technology Assessments (HTAs) increasingly influence pricing negotiations, emphasizing clinical benefits relative to costs.
Regulatory incentives, including orphan drug designation, facilitate premium pricing pipelines but may come under increased scrutiny, especially in cost-containment policies.
Risks and Opportunities
Risks:
- Regulatory delays or adverse clinical data could diminish market appeal.
- Evolving reimbursement policies may pressure prices downward.
- Market entry of cheaper biosimilars or generics.
Opportunities:
- Expanding indications can enlarge the TAM.
- Strategic partnerships with payers for value-based agreements.
- Demonstration of superior clinical outcomes can justify premium pricing.
Conclusion
The market for NDC 10094-0210 operates within a high-value, limited-competition niche primarily driven by clinical need, regulatory exclusivity, and pricing power. While current pricing remains robust, the landscape is susceptible to competitive, regulatory, and technological shifts. Stakeholders should adopt adaptive pricing strategies aligned with clinical value propositions, regulatory developments, and evolving reimbursement frameworks.
Key Takeaways
- Market potential for NDC 10094-0210 remains substantial in its niche, with high per-unit pricing supported by clinical demand and regulatory exclusivity.
- Pricing projections indicate stability with potential moderate declines over the medium to long term, especially upon patent expiry or competitive entry.
- Market dynamics are heavily influenced by regulatory policies, reimbursement environment, and competitor developments such as biosimilars.
- Strategic value demonstration and indication expansion are key to maintaining pricing power amidst evolving healthcare policies.
- Stakeholders should monitor legislative changes and technological innovations that could impact both pricing and market share.
FAQs
Q1: What factors determine the current price of NDC 10094-0210?
Current prices are influenced by clinical value, patent protection, manufacturing costs, and reimbursement negotiations, especially in niche markets with limited competition.
Q2: How soon can we expect prices to decline for this drug?
Price reductions typically occur within 5-10 years following patent expiry or the introduction of biosimilars, depending on competitive landscape and market dynamics.
Q3: What strategies can stakeholders use to maximize revenue from this drug?
Maximize revenue by expanding approved indications, securing favorable reimbursement agreements, demonstrating superior clinical outcomes, and engaging in value-based pricing negotiations.
Q4: How does regulatory status affect pricing projections?
Regulatory exclusivities, such as orphan drug status, support high pricing by limiting competition, whereas approvals of biosimilars or generics tend to reduce prices.
Q5: What are the risks associated with investing in this pharmaceutical product?
Risks include regulatory delays, clinical failures, market entry of competitors, and shifting reimbursement policies, all of which can impact pricing and market share.
Sources
[1] Federal Drug Administration (FDA) NDC Directory.
[2] IQVIA Healthcare Data & Market Trends.
[3] U.S. Food and Drug Administration. Orphan Drug Designations.
[4] Health Technology Assessment Reports.
[5] Industry Reports on Pharmaceutical Pricing Trends.
More… ↓
